Investors spank UTHR on 2nd FDA snub
This article was originally published in Scrip
Executive Summary
Apparently the quick resubmission and FDA acceptance last month of United Therapeutics' new drug application (NDA) for oral treprostinil diolamine extended-release tablets was too good to be true, with the agency handing out a second rejection, the firm disclosed in a brief statement on 25 March.